DoD Breast Cancer, Breakthrough Award Level 4 | W81XWH 21 BCRP BTA4

Opportunity Information: Apply for W81XWH 21 BCRP BTA4

The DoD Breast Cancer Research Program (BCRP) Breakthrough Award Level 4 (funding opportunity number W81XWH-21-BCRP-BTA4) is a highly competitive Department of Defense grant/cooperative agreement aimed at supporting ambitious breast cancer research with a clear line of sight to major, field-changing impact. The central goal is to back projects that have real breakthrough potential, meaning the work should not be a modest incremental step, but instead should credibly promise a new direction or intervention that is fundamentally better than what is already approved or currently in clinical development. Applicants are expected to define who the end beneficiaries will be, specifying the breast cancer patient populations or at-risk individuals who would ultimately benefit if the project succeeds, and to explain why the proposed work could accelerate progress toward ending breast cancer.

Level 4 is the most clinically advanced and operationally demanding tier within the Breakthrough Award structure. It is designed for large-scale projects intended to transform or revolutionize clinical management and/or prevention of breast cancer, and it explicitly requires human clinical trials. In practice, this means proposals must move beyond preclinical research and into rigorous testing in people, with the infrastructure, expertise, and execution plan expected of major clinical programs. Because of that scope, principal investigators are expected to demonstrate experience leading large, complex research efforts and to show they can successfully implement a clinical project, either through their own track record or via an established commitment from a collaborating clinical investigator. Applications also need to show practical readiness: when relevant, teams must document that they have access to the necessary datasets, human samples, cohorts, and critical reagents needed to deliver the trial and its associated analyses.

A key emphasis of Level 4 is operational and regulatory preparedness, especially for projects that require U.S. Food and Drug Administration involvement. If the work includes a regulated therapeutic or device, the application is expected to include proof that compliant clinical reagents are available and accessible, that the appropriate subject populations can be reached, and that patient recruitment projections are realistic and validated. Where applicable, the program expects that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) submission to the FDA has been made by the time the application is submitted. In other words, this mechanism is meant for projects that are not merely conceptually ready, but logistically and regulatorily positioned to move into or proceed through clinical testing.

The opportunity also places strong accountability on enrollment and trial execution through recruitment milestones. Applicants must lay out quarterly enrollment targets across all participating sites in the Statement of Work (Attachment 4). After award, successful teams work with the U.S. Army Medical Research Acquisition Activity (USAMRAA) to formalize recruitment milestones, and continued funding is tied to satisfactory progress against those agreed targets. This structure signals that the sponsor is prioritizing timely trial delivery and treats recruitment feasibility as a make-or-break component rather than an afterthought.

Collaboration is encouraged through an optional Partnering PI model designed for two principal investigators working as true intellectual partners. One PI serves as the Initiating PI and handles most submission-related administrative responsibilities, while the Partnering PI is expected to contribute substantially and comparably to the project concept, narrative, and statement of work. The program expects balanced effort and typically balanced funding between the two PIs unless there is a clear justification otherwise. Importantly, the partnership must be meaningful: the proposal should explain why the combined expertise is essential and why the work is stronger together than as separate projects. Arrangements that amount to one PI mainly supplying materials (like samples, animal models, or investigational agents) while the other PI does most of the research do not fit the intent. The announcement also discourages a single investigator from being listed as Partnering PI on multiple Level 4 applications unless each application tackles clearly distinct research questions. If funded, each PI is named on an individual award within the recipient organization, reflecting the expectation of shared leadership and accountability.

Team composition is treated as a critical success factor. Applications are expected to include a robust, appropriately staffed research team with the breadth of breast cancer-related expertise needed to conduct a large clinical trial and the associated translational, data, and operational work. Beyond scientific and clinical personnel, the program requires patient-centered input through consumer advocate involvement. Each application must include two or more breast cancer consumer advocates who are integrated into the project throughout planning and execution, not relegated to occasional attendance at meetings. These advocates must be individuals diagnosed with breast cancer who are active in advocacy organizations, must not be employees of participating organizations, and are expected to provide independent, objective input focused on relevance, feasibility, recruitment, oversight, and real-world impact for people with or at risk for breast cancer. The announcement also signals that advocates should be sufficiently informed about current breast cancer issues and have the background or training needed to contribute meaningfully to research discussions.

Administratively, the opportunity is offered by the Department of Defense, Department of the Army, through USAMRAA, and is listed under CFDA 12.420 (Science and Technology and other Research and Development). Eligibility is described as unrestricted, meaning it is broadly open to entity types unless otherwise limited by additional eligibility language in the full announcement. The posting indicates an expected single award for this cycle, underscoring the scale and competitiveness typical of Level 4 clinical trial mechanisms. The award ceiling is shown as 0 in the listing, which usually indicates applicants must rely on the program announcement itself for budget limits and that selection of Level 4 should be driven by scope alignment rather than trying to match a particular dollar figure.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Breast Cancer, Breakthrough Award Level 4" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jan 06, 2021.
• Applicants must submit their applications by Jun 23, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 BCRP BTA4

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: